Nonsurgical and Surgical Approach for Management of Cyclosporine-A and Nifedipine-Induced Gingival Overgrowth

Authors

  • Kodikara Mudiyanselage Chathurika Padma Kumari Faculty of Dental Sciences, University of Peradeniya, Sri Lanka
  • Aruni Tilakaratne Department of Restorative Dentistry, Faculty of Dentistry, Universiti Malaya, Malaysia

DOI:

https://doi.org/10.22452/adum.vol31.7

Keywords:

Gingival overgrowth, Drug-Induced, Cyclosporine, Nifedipine, Immunosuppressive medication, calcium channel blockers

Abstract

Gingival overgrowth (GO) is primarily a result of plaque-induced inflammatory process. However, GO is a modified inflammatory response due to predisposing factors such as systemic diseases or medications used by patients. GO is an established side effect related to some medications and hence referred to as medication-induced or drug-induced gingival overgrowth (DIGO). Over the past half a century, there has been an increasing trend in reporting of DIGO. The three main groups of predisposing medications for DIGO are anticonvulsants, immune-suppressants and calcium channel blockers. Among the calcium channel blockers, nifedipine is commonly used in the management of hypertension and other cardiovascular diseases. Immunosuppressive medication, cyclosporine-A is often prescribed for patients receiving organ trans­plants. When these predisposing medications are pre­scribed singly or in combination, there is an increased risk of DIGO as a clinical manifestation. A definitive diagnosis is important in the successful management of such patients. Timely diagnosis and effective dental care oriented for preventive and early therapeutic interventions would help in preventing serious complications with functional, aesthetic and systemic implications for the patient. Close collaboration with the medical and dental teams would invariably support the notion of integrated care tailored for specific treatment needs identified in these patients.

Downloads

Download data is not yet available.

References

Hassell TM, Hefti AF. Drug-induced gingival over¬growth: old problem, new problem. Crit Rev Oral Biol Med. 1991;2:103–37

Rateitschak PE, Hefti A, Loertscher R, Thiel G. Initial observation that cyclosporine-A induces gingival enlargement in man. J Clin Periodontol. 1983;10:237

Barclay S, Thomason JM, Idle JR, Seymour RA. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol. 1992;19:311–4

Heasman PA, Hughes FJ. Drugs, medications and periodontal disease. Br Dent J. 2014;217:411–419

Brown RS, Arany PR. Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis. Oral Dis. 2015;21:e51–e61

Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 1990;162:285-94

Castro LA, Elias LS, Oton-Leite AF, de Spíndula-Filho JV, Leles CR, Batista AC, et al. Long-term effects of nifedipine on human gingival epithelium: a histopathological and immunohistochemical study. J Oral Sci. 2010;(62):52-55

Dill RE, Iacopino AM. Myofibroblasts in phenytoin-induced hyperplastic connective tissue in the rat and in human gingival overgrowth. J Periodontol. 1997;68:375-80

Kataoka M, Kido J, Shinohara Y, Nagata T. Drug-induced gingival overgrowth - a review. Biol Pharm Bull. 2005;28:1817-1821

Murakami S, Mealey BL, Mariotti A, Chapple ILC. Dental plaque–induced gingival conditions. J Clin Periodontol. 2018;45(20):S17–27

Hatahira H, Abe J, Hane Y, Matsui T, Sasaoka S, Motooka Y, et al. Drug-induced gingival hyperplasia: A retrospective study using spontaneous reporting system databases. J Pharm Health Care Sci. 2017;3:19

National Institute of Dental and Craniofacial Research (Nidcr); U.S. Department Of Health And Human Services (2011). Dental Management of the Organ Transplant Patient; Improving the Nation’s Oral Health. National Institutes of Health, NIH Publication

Malek R, Houari BE, Kissa K. Periodontal Management of Cyclosporin A-Induced Gingival Overgrowth: A Nonsurgical Approach. Case Rep Dent. 2019;2019:8609547

Dongari-Bagtzoglou AD. Drug-associated gingival enlargement. Research, Science and Therapy Committee, American Academy of Periodontology. Informational paper. J Periodontol. 2004;75:1424–31

Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol. 1996;23:165-175

Seymour RA, Heasman PA. Drugs and the periodontium. J Clin Periodontol. 1988;15(1):1-16

Uzel MI, Kantarci A, Hong HH, et al. Connective tissue growth factor in drug-induced gingival overgrowth. J Periodontol. 2001;72(7):921-931

O'Valle F, Mesa F, Aneiros J, Gomez-Morales M, Lucena MA, Ramirez C, Revelles F, Moreno E, Navarro N, Cahaliero T, Masseroli M, Garcia del Moral R. Gingival overgrowth induced by nifedipine and cyclosporin A. Clinical and morphometric study with image analysis. J Clin Periodontol. 1995;22:591-597

Nanda T, Singh B, Sharma P, Arora KS. Cyclosporine A and amlodipine induced gingival overgrowth in a kidney transplant recipient: case presentation with literature review. BMJ Case Rep. 2019;12(5):381

Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodontol. 1993;20:37-40

Ramalho VC, de Amorim RF, Veiga DC, Pontes MJ, Valença AM. Analysis of the influence of mechanical control of biofilm and use of cyclosporine on gingival enlargement. Acta Cir Bras. 2007;22(3):179-183

Mavrogiannis M, Ellis JS, Seymour RA, Thomason JM. The management of drug-induced gingival overgrowth. J Clin Periodontol. 2006;33(6):434-439

Downloads

Published

2024-09-25

Issue

Section

Case Report